A caveat for OV-Monitor (CA 125 antigen) measurement: something is improving, something is not

Articles in the same Issue

1. Renal function – estimation of glomerular filtration rate
2. Research translation: a new frontier for clinical laboratories
3. Association of APOA5 c.553G>T polymorphism with type 2 diabetes mellitus in a Chinese population
4. MTRR 66A>G polymorphism in relation to congenital heart defects
5. Increased homocysteine in heart failure: a result of renal impairment?
6. Urine flow cytometry and detection of glomerular hematuria
7. Chymotrypsin effects on the determination of sperm parameters and seminal biochemistry markers
8. Evaluation of cardiac involvement following major orthopedic surgery
9. Increased sensitivity in detecting renal impairments by quantitative measurement of marker protein excretion compared to detection of pathological particles in urine sediment analysis
10. Clinical chemistry reference values for 75-year-old apparently healthy persons
11. Serum pro-hepcidin concentrations and their responses to oral iron supplementation in healthy subjects manifest considerable inter-individual variation
12. Comparability of five analytical systems for the determination of triiodothyronine, thyroxine and thyroid-stimulating hormone
13. Automated analysis of pleural fluid total and differential leukocyte counts with the Sysmex XE-2100
14. Automation and validation of a fast method for the assessment of in vivo oxidative stress levels
15. Analytical validation of the new plasma calibrated Accu-Chek^® Test Strips (Roche Diagnostics)
16. Use of insulin immunoassays in clinical studies involving rapid-acting insulin analogues: Bi-insulin IRMA preliminary assessment
17. Analytical and clinical evaluation of a new heart-type fatty acid-binding protein automated assay
18. A caveat for OV-Monitor (CA 125 antigen) measurement: something is improving, something is not
19. Reply to the letter written by Dorizzi et al.